Chapter 5: eXtended EudraVigilance Product Report Acknowledgement Message - Detailed guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the EMA

Submitted by Anonymous (not verified) on 10 January 2025 - 8:35

Chapter 5: eXtended EudraVigilance Product Report Acknowledgement Message - Detailed guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the EMA

Chapter 3.II: XEVPRM detailed user guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the EMA

Submitted by Anonymous (not verified) on 10 January 2025 - 8:32

Chapter 3.II: XEVPRM detailed user guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the EMA

Committee for Advanced Therapies (CAT): 6-8 November 2024, European Medicines Agency, Amsterdam, the Netherlands, from 6 November 2024 to 8 November 2024

Submitted by Anonymous (not verified) on 9 January 2025 - 15:00

Committee for Advanced Therapies (CAT): 6-8 November 2024, European Medicines Agency, Amsterdam, the Netherlands, from 6 November 2024 to 8 November 2024

Human medicines European public assessment report (EPAR): Fluad Tetra, influenza vaccine (surface antigen, inactivated, adjuvanted), Date of authorisation: 20/05/2020, Revision: 10, Status: Authorised

Submitted by Anonymous (not verified) on 9 January 2025 - 13:41

Human medicines European public assessment report (EPAR): Fluad Tetra, influenza vaccine (surface antigen, inactivated, adjuvanted), Date of authorisation: 20/05/2020, Revision: 10, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness